SK Bioscience
SK Bioscience is a South Korean pharmaceutical company focused on the development and manufacturing of vaccines. The company is notable for introducing SKYCellflu, the first cell culture influenza vaccine in Korea, and has since expanded its portfolio to include the SKYCellflu Quadrivalent prefilled syringe and a 13-valent Pneumococcal Conjugate Vaccine. In addition to these licensed products, SK Bioscience is actively engaged in the development of several other vaccines, including a recombinant rotavirus vaccine, a new typhoid conjugate vaccine, and an innovative pneumococcal vaccine, often in collaboration with external partners. The company is dedicated to building a robust infrastructure for continuous vaccine development, positioning itself as a key player in the global vaccine landscape.
3 past transactions
Fina Biosolutions
Corporate Round in 2024
Fina Biosolutions is a biotechnology company focused on developing and collaborating on innovative vaccine conjugates aimed at preventing life-threatening diseases. The company employs proprietary techniques to conjugate, purify, and manufacture complex vaccine conjugates. By utilizing advanced bioconjugation methods, Fina Biosolutions provides a range of services including protein expression, purification, immunoassay design, analytics, as well as training and consulting. These capabilities not only enhance the accessibility of life-saving vaccines but also work to reduce the associated costs, ensuring that more individuals can benefit from essential vaccination.
Sunflower Therapeutics
Seed Round in 2024
Sunflower Therapeutics is a biotechnology company focused on advancing protein manufacturing solutions to enhance global access to biological medicines. By employing strain engineering and integrated process development, the company aims to create efficient, automated systems for protein production. These innovations are designed to support a wide range of applications, including new medicines and food products, allowing clients to significantly reduce the time and costs associated with developing and manufacturing biologics. Sunflower Therapeutics emphasizes values such as wellness, integrity, ethics, equity, community, and efficiency in its operations, reflecting its commitment to benefiting the global population.
Novavax
Post in 2023
Novavax Inc., established in 1987 and headquartered in Gaithersburg, Maryland, is a late-stage biotechnology company dedicated to discovering, developing, and commercializing vaccines to prevent serious infectious diseases worldwide. Its primary focus lies in advancing vaccine candidates through clinical trials, with notable projects including ResVax for RSV in infants via maternal immunization (Phase III), NanoFlu for seasonal influenza in older adults (Phase III), and NVX-CoV2373 for COVID-19 (preclinical). Novavax's proprietary Matrix-M adjuvant enhances immune response and enables lower antigen doses. The company collaborates globally to address urgent health needs, with Europe being its primary revenue source.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.